Merck’s $1.1 billion bet on Peloton Therapeutics is starting to pay off. Belzutifan, one of the most lucrative assets Merck picked up through its 2019 …
Aeromics, Inc. (“Aeromics” or “the Company”), a privately-held, clinical-stage pharmaceutical company focused on controlling cerebral edema for people affected by disabling and life-threatening severe ischemic …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
